O’Cearbhaill, R. E., Moore, K. N., Yeku, O., Liu, J. F., Bouberhan, S., Hamilton, E. P., Hou, J. Y., Van Nieuwenhuysen, E., Papadimitriou, K., Yoo, S.-Y., Govindraj, S., Brouwer-Visser, J., Peterman, M., Schmidt, T., Barnes, B., Madia, P., Zhu, M., Uldrick, T. S., Miller, E. A., & O’Malley, D. (2023). 754P Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study. Annals of Oncology, 34, S516–S517. https://doi.org/10.1016/j.annonc.2023.09.1933